Skip to main content
. 2016 Jul 22;7(36):57932–57942. doi: 10.18632/oncotarget.10773

Figure 6. RabGGTA mediates anti-tumor effects of ZOL.

Figure 6

A. Morphological changes after lentiviral transduction of U87 glioma cells and SK262 and SK102 patient-derived GBM cell lines, targeting FNTA and RabGGTA genes. B. Western blotting depicting expression of FNTA and RabGGTA following shRNA expression. Decreased RabGGTA expression is associated with LC3-II/LC3-I conversion, very similar to cell after ZOL treatment. C. Cell viability in cells following shRNA-induced knockdown of FNTA and RabGGTA demonstrates decreased viability only after RabGGTA knockdown (U87 cell viability 99.3%±4.0% Vs. 27.3%±5.1%, p=0.002) but not FNTA (99.3% ±4.0% Vs. 103.1%±5.6%, p=0.24). GBM patients' primary cell lines SK102 and SK262 also have similar results.